# Relationship Between Immunity and Metabolism in Patients Receiving Immune Checkpoint Inhibitors for Advanced Cancer. ( RIMEC )

> **NCT04808817** · NA · ACTIVE_NOT_RECRUITING · sponsor: **Assistance Publique - Hôpitaux de Paris** · enrollment: 48 (actual)

## Conditions studied

- Metabolism Disorder
- Cancer
- Immune Checkpoint Inhibitors

## Interventions

- **DIAGNOSTIC_TEST:** calorimetry, impedance measurement at baseline and after 3 months of treatment

## Key facts

- **NCT ID:** NCT04808817
- **Lead sponsor:** Assistance Publique - Hôpitaux de Paris
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2021-05-10
- **Primary completion:** 2024-04-09
- **Final completion:** 2024-10-09
- **Target enrollment:** 48 (ACTUAL)
- **Last updated:** 2024-07-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04808817

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04808817, "Relationship Between Immunity and Metabolism in Patients Receiving Immune Checkpoint Inhibitors for Advanced Cancer. ( RIMEC )". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT04808817. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*